Brazil's Federal Court of Accounts has given the Ministry of Health 60 days to present delivery metrics after finding widespread delays in Fiocruz medicine supplies.
The unanimous decision, approved during a plenary session in late August 2026 under Acórdão 2317/2026, requires federal health officials to provide partial and consolidated data on medicine delivery deadlines. The court also ordered the Ministry of Health to provide a technical justification for why only 3% of shipments arrived on time during the first half of 2024 under Technical Cooperation Agreement 02/2023, alongside a detailed account of measures taken to address the backlogs.
According to a partial execution report analyzed by the court, known formally as the Tribunal de Contas da União, contractors delivered 43% of the total medicine volume requested for the period. However, out of the shipments actually delivered, only 3% met the agreed delivery schedule, leaving 97% arriving past their deadline. Audit officials clarified that the 97% figure measures delivery punctuality and does not mean that 97% of the drugs failed to reach the health system.
The Federal Court of Accounts serves as the independent audit and spending watchdog for Brazil's federal government. The Ministry of Health oversees the Sistema Único de Saúde, Brazil's universal public healthcare system, which relies on public manufacturers like the Oswaldo Cruz Foundation, known as Fiocruz, to supply essential pharmaceutical products nationwide.
Audit Identifies Supply Chain Bottlenecks and Cyberattack
Technical Cooperation Agreement 02/2023 forms part of a broader partnership between the Ministry of Health and Fiocruz to manufacture and distribute strategic health inputs for the public health network. The specific agreement covers high-complexity pharmaceuticals under the Specialized Component of Pharmaceutical Assistance, which funds treatments guided by official clinical protocols.
The delayed shipments involved several specialized medications. These include cabergoline 0.5 mg, used to treat hormonal disorders and Parkinson's disease, and pramipexole in 0.125 mg and 0.25 mg doses, prescribed for Parkinson's disease and restless legs syndrome. The order also encompassed sevelamer 800 mg, a phosphate binder for kidney disease patients on dialysis, and tacrolimus in 1 mg and 5 mg doses, an immunosuppressive drug that prevents organ transplant rejection.
Auditors determined that the execution of these cooperation agreements relies heavily on advance demand planning and active monitoring. They attributed the delivery delays to multiple supply chain and logistical bottlenecks, including delayed deliveries of raw materials, complex logistics, extended partner manufacturing schedules, import procedures, batch clearance protocols, and scheduling constraints at state health secretariats.
The audit also highlighted a severe external disruption. In August 2023, a cyberattack targeted a key Fiocruz production unit responsible for manufacturing public medications. Federal auditors noted that the cyber incident disrupted the entire manufacturing chain, creating ripple effects that delayed final product deliveries into 2024.
Administrative shortcomings within the Ministry of Health further compounded the delays. Auditors found that ministry officials repeatedly delayed the formalization of distribution schedules, known as pautas de distribuição, which designate where medicines must be sent. Delays in releasing budget funds and approving these schedules created severe knock-on effects, stalling billing, batch releases, and final transport.
Pre-emptive Production Risks and National Stock Analysis
To prevent total supply interruptions while awaiting official ministry paperwork, Fiocruz initiated early manufacturing of estimated medicine quantities. While auditors acknowledged that advance production helped maintain supply continuity, they warned that the practice introduces significant operational risks.
The court noted that manufacturing drugs before demand is formal can lead to discrepancies between produced stock and actual state orders. Additionally, drugs produced early spend months in storage before distribution, leaving them with shorter remaining shelf lives when they finally reach patients. Auditors urged the ministry to align its administrative timelines, funding releases, and distribution schedules with the lead times needed for drug synthesis, importation, and delivery.
Despite the high rate of unpunctual deliveries, the court did not find evidence of a nationwide medicine shortage. The Ministry of Health maintains contingency protocols and stock reallocation mechanisms designed to transfer supplies between states during localized delays.
However, auditors cautioned that existing data systems make it impossible to determine the true impact of delays on clinic shelves. The Ministry of Health cited severe data lags, incompatible state logistics systems, and an absence of real-time inventory tracking across state and municipal health departments, preventing federal oversight of actual stock levels.
Flaws in Delivery Monitoring and Late Data Collection
The audit court identified critical flaws in how health officials monitored agreement performance. Although the ministry established tracking tools, qualification sheets, technical opinions, and digital dashboards to log shipments, auditors found that definitive evaluations were deferred until agreements officially closed.
The reporting judge emphasized that assessing punctuality only at the end of a multi-year contract strips indicators of their practical management value. Evaluating performance periodically would allow health managers to spot delays early and implement corrective measures while contracts remain active.
Under Acórdão 2317/2026, the court mandated that the Ministry of Health report full performance metrics for both 2024 and 2025 within 60 days under the "On-time medicine delivery index." The directive applies to Technical Cooperation Agreements 02/2023 and 03/2023 regardless of whether the contracts have been formally concluded.
In response to earlier audit findings, the Ministry of Health introduced the Project for Improvement of Strategic Health Inputs Management, a comprehensive initiative designed to restructure the public health supply chain from initial demand forecasting through distribution and governance.
The restructuring project spans nine core operational areas. These include process redesign, standardized contracting documents, fixed workflow timelines, an annual procurement calendar, inventory turnover management, modernization of the Integrated Material Administration System, indicator dashboards, state logistics mapping, and digital transformation initiatives.
While acknowledging the ministry's planning efforts, the court observed that key components remained under development when the audit concluded. Auditors stated there was insufficient evidence to prove sustainable operational improvements, such as reduced waste from expired drugs or increased purchasing efficiency, and ordered continued monitoring of the health ministry.
Ministry and Fiocruz Rebut Audit Findings
In statements provided to CNN Brasil, both the Ministry of Health and Fiocruz asserted that overall delivery commitments under Technical Cooperation Agreement 02/2023 were fully satisfied for 2024 and 2025.
Fiocruz stated that its annual delivery schedules for 2024 and 2025 under the agreement were completely fulfilled. The foundation explained that the cooperation agreement serves as a flexible framework to align public health demand with manufacturing capacity, adding that weekly tracking by the Ministry of Health confirmed no shortages occurred in states or municipalities.
Addressing delivery adjustments, Fiocruz stated that schedule modifications usually stem from delays in acquiring imported raw materials. The foundation confirmed that a cyberattack hit systems at its main pharmaceutical unit, Farmanguinhos, temporarily affecting production and shipping, but stated that corrective measures quickly restored operations and protected contract goals.
The Ministry of Health separately confirmed that all drug quantities planned under the agreement for 2024 and 2025 were delivered in full without causing shortages. Health officials emphasized that weekly monitoring ensures continuous distribution while public laboratory capacity expands to meet long-term public health needs.
